Jan J. Molenaar

11.3k total citations
91 papers, 3.2k citations indexed

About

Jan J. Molenaar is a scholar working on Neurology, Molecular Biology and Oncology. According to data from OpenAlex, Jan J. Molenaar has authored 91 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Neurology, 50 papers in Molecular Biology and 32 papers in Oncology. Recurrent topics in Jan J. Molenaar's work include Neuroblastoma Research and Treatments (67 papers), Cancer, Hypoxia, and Metabolism (19 papers) and Cell death mechanisms and regulation (18 papers). Jan J. Molenaar is often cited by papers focused on Neuroblastoma Research and Treatments (67 papers), Cancer, Hypoxia, and Metabolism (19 papers) and Cell death mechanisms and regulation (18 papers). Jan J. Molenaar collaborates with scholars based in Netherlands, United States and Germany. Jan J. Molenaar's co-authors include Rogier Versteeg, Jan Köster, Huib N. Caron, Peter van Sluis, Marli E. Ebus, Linda J. Valentijn, Godelieve A.M. Tytgat, Fieke Lamers, Linda Schild and Danny A. Zwijnenburg and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Jan J. Molenaar

88 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan J. Molenaar Netherlands 32 1.8k 1.5k 932 894 322 91 3.2k
Yaël P. Mossé United States 35 2.4k 1.3× 2.7k 1.8× 1.7k 1.8× 1.3k 1.5× 494 1.5× 96 4.6k
S. D. Gillies United States 13 980 0.5× 1.4k 0.9× 390 0.4× 872 1.0× 242 0.8× 18 2.2k
José Cameselle‐Teijeiro Spain 39 1.6k 0.9× 225 0.1× 670 0.7× 1.6k 1.8× 545 1.7× 143 4.3k
Roeland F. de Wilde Netherlands 23 1.2k 0.7× 912 0.6× 529 0.6× 2.4k 2.7× 140 0.4× 63 3.8k
Arnulfo Mendoza United States 26 1.5k 0.8× 312 0.2× 636 0.7× 965 1.1× 192 0.6× 51 2.8k
Raushan T. Kurmasheva United States 27 1.3k 0.7× 315 0.2× 366 0.4× 814 0.9× 190 0.6× 120 2.3k
Kristian W. Pajtler Germany 24 1.2k 0.6× 555 0.4× 371 0.4× 284 0.3× 178 0.6× 91 2.2k
Socorro Marıá Rodríguez-Pinilla Spain 30 1.6k 0.9× 203 0.1× 1.1k 1.1× 2.0k 2.2× 274 0.9× 97 3.8k
Nicolas Skuli United States 28 1.6k 0.9× 203 0.1× 1.3k 1.4× 444 0.5× 156 0.5× 45 2.6k
Nicolas Sévenet France 20 2.3k 1.3× 311 0.2× 329 0.4× 575 0.6× 271 0.8× 51 3.1k

Countries citing papers authored by Jan J. Molenaar

Since Specialization
Citations

This map shows the geographic impact of Jan J. Molenaar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan J. Molenaar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan J. Molenaar more than expected).

Fields of papers citing papers by Jan J. Molenaar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan J. Molenaar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan J. Molenaar. The network helps show where Jan J. Molenaar may publish in the future.

Co-authorship network of co-authors of Jan J. Molenaar

This figure shows the co-authorship network connecting the top 25 collaborators of Jan J. Molenaar. A scholar is included among the top collaborators of Jan J. Molenaar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan J. Molenaar. Jan J. Molenaar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Molenaar, Jan J., Maria V. Papadopoulou, Ronald R. de Krijger, et al.. (2025). γδ T cells are the prime antitumoral T cells in pediatric neuroblastoma. Life Science Alliance. 8(11). e202503249–e202503249.
2.
Kim, Seok‐Young, Marijn A. Vermeulen, Femke Ringnalda, et al.. (2025). Organoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer. Science Advances. 11(9). eadq1724–eadq1724. 2 indexed citations
3.
Boltjes, Arjan, Florie Reynaud, Ilse Timmerman, et al.. (2024). Neuroblastoma plasticity during metastatic progression stems from the dynamics of an early sympathetic transcriptomic trajectory. Nature Communications. 15(1). 9570–9570. 1 indexed citations
4.
Kamili, Alvin, Jennemiek van Arkel, Marlinde L. van den Boogaard, et al.. (2024). Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma. SHILAP Revista de lepidopterología. 3. 100168–100168. 4 indexed citations
5.
Eleveld, Thomas F., Linda Schild, Lindy K. Alles, et al.. (2023). MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma. Frontiers in Oncology. 13. 1130034–1130034. 6 indexed citations
6.
Molenaar, Jan J., et al.. (2023). Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges. European Journal of Cancer. 194. 113347–113347. 5 indexed citations
7.
Verwiel, Eugène T.P., Lennart Kester, Jan J. Molenaar, et al.. (2023). Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGS. BMC Cancer. 23(1). 618–618. 9 indexed citations
8.
Chen, Celine, Ana Isabel Enríquez Rodríguez, Jan Köster, et al.. (2022). Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours. European Journal of Cancer. 170. 196–208. 9 indexed citations
9.
Cornel, Annelisa M., Satyaki Sengupta, Judith Wienke, et al.. (2022). Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. Journal for ImmunoTherapy of Cancer. 10(12). e005002–e005002. 22 indexed citations
10.
Vloed, Fanny De, Martijn Risseeuw, Jan J. Molenaar, et al.. (2022). Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma. European Journal of Medicinal Chemistry. 247. 115033–115033. 23 indexed citations
11.
Bate-Eya, Laurel T., Lindy K. Alles, Linda Schild, et al.. (2021). High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells. Molecular Cancer Therapeutics. 20(6). 1161–1172. 9 indexed citations
12.
Vassal, Gilles, Peter J. Houghton, Stefan M. Pfister, et al.. (2021). International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer. Molecular Cancer Therapeutics. 20(8). 1462–1468. 16 indexed citations
13.
Boogaard, Marlinde L. van den, Rurika Oka, Linda Schild, et al.. (2021). Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma. Proceedings of the National Academy of Sciences. 118(36). 17 indexed citations
14.
Drent, Esther, Sander R. van Hooff, Waleed M. Kholosy, et al.. (2021). αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression. Journal of Personalized Medicine. 11(9). 923–923. 9 indexed citations
15.
Wienke, Judith, Miranda P. Dierselhuis, Godelieve A.M. Tytgat, et al.. (2020). The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology. European Journal of Cancer. 144. 123–150. 129 indexed citations
16.
George, Sally L., Federica Lorenzi, David S. King, et al.. (2020). Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma. EBioMedicine. 59. 102971–102971. 47 indexed citations
17.
Tas, Michelle L., Kathelijne C.J.M. Kraal, Godelieve A.M. Tytgat, et al.. (2019). Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. Pediatric Blood & Cancer. 67(4). e28061–e28061. 16 indexed citations
18.
Eleveld, Thomas F., Linda Schild, Jan Köster, et al.. (2018). RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma. Cancer Research. 78(21). 6297–6307. 40 indexed citations
19.
Moreno‐Smith, Myrthala, Zaowen Chen, Ling Tao, et al.. (2017). p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clinical Cancer Research. 23(21). 6629–6639. 20 indexed citations
20.
Dolman, M. Emmy M., Evon Poon, Marli E. Ebus, et al.. (2015). Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research. 21(22). 5100–5109. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yaël P. Mossé Breakdown of academic impact, for papers by S. D. Gillies Breakdown of academic impact, for papers by José Cameselle‐Teijeiro Breakdown of academic impact, for papers by Roeland F. de Wilde Breakdown of academic impact, for papers by Arnulfo Mendoza Breakdown of academic impact, for papers by Raushan T. Kurmasheva Breakdown of academic impact, for papers by Kristian W. Pajtler Breakdown of academic impact, for papers by Socorro Marıá Rodríguez-Pinilla Breakdown of academic impact, for papers by Nicolas Skuli Breakdown of academic impact, for papers by Nicolas Sévenet
Rankless by CCL
2026